StreetAlpha.app
Home › Stocks › TSHA

Taysha Gene Therapies, Inc. (TSHA)

Healthcare
$4.00
▼ −1.48%
LAST CLOSE · NOV 17

Taysha Gene Therapies develops gene therapies for severe brain disorders, with its lead candidate aimed at Rett syndrome. It last closed at $4.00 on Nov 17, down 1.48% on the day. TSHA last reported earnings on Tue, Aug 11, 2026.

AI Auto Pilots
Is TSHA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$5.5M
−13.1% vs a year ago
Net income
−$156.0M
−2844.6% margin
EPS (diluted)
−$0.42
Free cash flow
−$141.7M
−2582.6% margin
Valuation
Market cap
$1.3B
326.0M shares
P/E
–
No P/E while losing money
Price to sales
237.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$422.8M
At Sep 30
Debt
$47.3M
At Sep 30
Shareholder equity
$357.0M
Shares outstanding
326.0M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $2.5M$2.5MFY2022FY2023: $15.5M$15.5MFY2023FY2024: $8.3M$8.3MFY2024FY2025: $9.8M$9.8MFY2025

From TSHA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · After the close (AMC)
Reported EPS
-$0.13
vs -$0.11 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±14.4%
Priced in before that report
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated TSHA in the past 90 days.
Average 12-month target
No price targets on TSHA in the past 90 days.
Latest rating changes
Goldman SachsMaintained
Jul 21Buy$13
NeedhamMaintained
Jun 30Buy$12
BairdMaintained
Jun 30Buy$15
BMO CapitalMaintained
Jun 23Buy$14
B of A SecuritiesMaintained
Jun 23Buy$10
DateFirmActionRatingPrice target
Jul 21Goldman SachsMaintainedBuy$13
Jun 30NeedhamMaintainedBuy$12
Jun 30BairdMaintainedBuy$15
Jun 23BMO CapitalMaintainedBuy$14
Jun 23B of A SecuritiesMaintainedBuy$10
Loading…

Technical Analysis

TSHA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 4% below its 20 day and 11% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot S1 at $3.93, and the nearest resistance the Pivot R1 at $4.08.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$7.3052 week high+82.5%
$5.29200 day average+32.3%
$5.24100 day average+31.0%
$4.4350 day average+10.7%
$4.26Swing high (Oct 21)+6.5%
$4.1520 day average+3.8%
$4.08Pivot R1+2.0%
$4.00Pivot+0.0%
$4.00Last close
$3.93Pivot S1−1.7%
$3.92Swing low (Nov 3)−2.0%
$3.4652 week low−13.5%
Indicators
RSI (14)41.94Middle of its rangeNeutral
MACD-0.08Above its signal lineBullish
Stochastic21.9Middle of its rangeNeutral
ADX (14)14.4No clear trend
Williams %R-86.9Oversold below −80, overbought above −20Oversold
CCI (20)-102.6Oversold below −100, overbought above 100Oversold
Rate of change−2.2%Change over 10 sessionsBearish
ATR (14)$0.27Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TSHA

What happened before

See how TSHA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow TSHA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How TSHA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in TSHA in the last 90 days.

Loading…

See today’s whale options flow across the market →

TSHA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲116 buying vs 81 selling
  • ▲Held by funds +5.2 pts
  • ▼Funds holding -4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding205209−1.9%
In funds' top 1035−40.0%
Held by funds97.1%91.9%+5.2 pts
New / increased25 / 9141 / 99−17.1%
Reduced / sold out53 / 2841 / 23+26.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TSHA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TSHA is in one of them and how their past TSHA trades turned out.

TSHA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TSHA in an article yet. Here's the latest on the wider market.

About Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company based in Dallas, Texas, that develops gene therapies for severe diseases of the central nervous system. Its lead candidate, TSHA-102, is being tested for Rett syndrome, a genetic disorder that mainly affects girls and causes loss of speech, hand use and motor skills. The treatment is still in clinical trials, and its intended users are patients with Rett syndrome and their caregivers.

Headquarters
Dallas, TX